Analysis
ADARx Pharmaceuticals filed a Form S-1 with the SEC on September 4 for a proposed Nasdaq Global Market listing under the ticker ADRX, per its EDGAR filing. Terms and size were not disclosed, the standard posture for a first filing. J.P. Morgan, Morgan Stanley, TD Cowen, UBS Investment Bank and LifeSci Capital are underwriting -- Morgan Stanley is also a lead underwriter on the SB Energy and Anthropic listings Pulse has previously covered this cycle.
The Pipeline
The company develops siRNA therapeutics -- small interfering RNA drugs that silence a target gene's expression rather than blocking a protein after it is made. Its wholly owned pipeline runs three clinical programs: agazisiran, targeting complement factor B for complement-mediated disease; onvuzosiran, targeting plasma kallikrein for hereditary angioedema, which carries FDA Fast Track and orphan drug designations; and ADX-626, targeting Factor XI for secondary stroke prevention. Two preclinical candidates follow -- ADX-077 in obesity and ADX-199 targeting APP in neurons for neurodegenerative disease, per Endpoints News.
“That is the hard problem in the field and the reason ADX-199, aimed at neurons, is the most interesting item in the pipeline even though it is the least advanced.”
siRNA is one of the few modalities where the commercial case is proven rather than theoretical. Alnylam built a multi-billion-dollar franchise on it and now trades as a large-cap biotech; Arrowhead and Dicerna established the second wave, with Novo Nordisk acquiring Dicerna for $3.3 billion in 2021. The category's appeal is durability -- some approved siRNA drugs dose twice a year -- which matters enormously in chronic disease adherence.
ADARx's positioning is extrahepatic delivery: getting siRNA to work outside the liver, where the established conjugate chemistry reliably lands. That is the hard problem in the field and the reason ADX-199, aimed at neurons, is the most interesting item in the pipeline even though it is the least advanced. Its Factor XI program competes directly with anticoagulant efforts at Bayer, BMS/Janssen and Anthos, a crowded field where the differentiating claim is bleeding risk rather than efficacy.
The Market Backdrop
The backdrop matters more than the pipeline for pricing. Biotech IPOs have been the quietest corner of a very loud 2026 listing market, with generalist capital concentrated in AI and infrastructure. Crossover investors have been selective, and companies without a partnership or a Phase 2 readout have generally waited. ADARx's AbbVie relationship is the credibility marker underwriters will use, and its three clinical assets give it more shots on goal than the typical filer.
The risk is the usual one, stated plainly: three clinical programs, none approved, in indications with entrenched competitors, funded by an offering into a market that has repriced clinical-stage biotech hard since 2021. Secondary-market marks have put the company under $1 billion, which sets a modest bar for the deal to clear.
ADARx is based in San Diego, which remains the densest cluster for RNA therapeutics talent outside Cambridge, Massachusetts -- Arrowhead, Avidity and Ionis all built there, and Ionis in particular seeded much of the antisense and siRNA expertise the region now draws on. The company has raised several hundred million dollars privately, with secondary-market platforms marking it in the high hundreds of millions before this filing, which is the rough anchor a pricing range will be negotiated against.
The filing to watch for is the price range amendment. In a market this selective, the gap between filing and pricing is where biotech deals quietly die.
